Category : Clinical Research, Pharma & Healthcare Financing

Mölnlycke® Health Care, a global leader in MedTech, headquartered in Gothenburg, Sweden, today celebrates the groundbreaking of a major expansion to its wound care manufacturing capacity in Brunswick,...

GCCL (Global Clinical Central Lab), a South Korea-based leading provider of clinical trial sample analysis, and Frontage Laboratories, Inc., a USA based full-service contract research organization (CRO), announced...

Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, today announces successful clinical data from the aXess...

VedaBio, a pioneering biotechnology company transforming molecular detection, today announced a Series A extension alongside a strategic agreement with Siemens Healthineers. Together, these commitments total...

WeDosify becomes CLM’s first commercially available product – delivering data-driven, adaptive dosing recommendations to improve GLP-1 adherence. Informed by 29 studies and 15,000+ patient profiles;...

Celltrion today announced that Health Canada has approved Stoboclo® and Osenvelt® (CT-P41), biosimilars referencing Prolia® and Xgeva®, respectively for all indications of reference products.1,2 “The approval of Stoboclo...

‘FORTIFY’ Selects FAI-Score™ as Primary Outcome Measure, and Caristo as Worldwide Imaging Core Lab for Coronary Inflammation and Plaque Measurement and Monitoring Caristo Diagnostics, on a mission...

Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% lower risk of major cardiovascular events...

Results Support Potential for STAR-0310 to be Best-in-Class OX40 Antagonist — STAR-0310 Exhibits Longest-in-Class Half-Life of 68 Days and Cytokine Suppression Lasting At Least 20...

Extension financing led by new investor Bpifrance, with renewed participation from all existing shareholders, AdBio Partners, CDTI Innovación, Columbus Venture Partners, European Innovation Council (EIC),...

Funding to advance first-in-class pan-ROCK inhibitor through Phase 2a testing in PAH and ILD-PH patients Topline data from ROC-101 Phase 1 study demonstrate favorable safety...

Initial patients dosed in multiple cohorts of the Phase 1 dose-expansion study assessing KTX-1001 in combination with standard of care and mezigdomide for t(4;14) multiple myeloma...

The Trial Evaluates a Combined PCI Approach Using Drug-Coated Balloons and Drug-Eluting Stents Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced...